# Contineum (CTNM) — News

CTNM · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/ctnm/news

## Recent headlines

- [Contineum Therapeutics, Inc.: Jonestading raises target price to $30 from $24](https://www.ainvest.com/news/contineum-therapeutics-jonestading-raises-target-price-30-24-2610) — AInvest Wire, Oct 14, 2026
  Jonestading has raised its target price for Contineum Therapeutics, Inc. (CTNM) to $30 from $24, reflecting a positive reassessment of the company’s outlook. The adjustment follows recent developments in the company’s pipeline and market positioning. Analysts have noted improved confidence in the…
- [Contineum Therapeutics, Inc.: Baird cuts to neutral rating; cuts target price to $14 from $19](https://www.ainvest.com/news/contineum-therapeutics-baird-cuts-neutral-rating-cuts-target-price-14-19-2610) — AInvest Wire, Oct 13, 2026
- [Contineum Therapeutics, Inc.: Leerink Partners cuts target price to $22 from $25](https://www.ainvest.com/news/contineum-therapeutics-leerink-partners-cuts-target-price-22-25-2609) — AInvest Wire, Sep 15, 2026
  Leerink Partners has revised its target price for Contineum Therapeutics, Inc. (CTNM) to $22 from $25, reflecting a downward adjustment in its price forecast for the stock. This change comes amid a broader range of analyst opinions, with five Wall Street analysts currently providing ratings for the…
- [Contineum Therapeutics: Analyses of data including exploratory endpoints are ongoing](https://www.ainvest.com/news/contineum-therapeutics-analyses-data-including-exploratory-endpoints-ongoing-2609) — AInvest Wire, Sep 14, 2026
  Contineum Therapeutics continues to analyze data from its ongoing clinical trials, with a focus on both primary and exploratory endpoints. The company has indicated that these analyses are in progress and will provide further insights into the therapeutic potential of its pipeline candidates. As…
- [Contineum Therapeutics, - Phase 2 Moonlight-1 trial did not meet primary efficacy endpoint](https://www.ainvest.com/news/contineum-therapeutics-phase-2-moonlight-1-trial-meet-primary-efficacy-endpoint-2609) — AInvest Wire, Sep 14, 2026
  Contineum Therapeutics, Inc. (NASDAQ: CTNM) has reported that the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307, conducted in collaboration with Johnson & Johnson, did not meet its primary efficacy endpoint for the treatment of major depressive disorder (MDD). The trial, which enrolled 107 adult…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).